Freenome

A biotechnology company that leverages an AI genomics platform to create noninvasive blood tests for early cancer detection and precision oncology treatments. Freenome's technology differentiates itself by integrating machine learning with multi-omics data to identify cancer biomarkers at early stages, potentially improving patient outcomes and treatment efficacy. The primary beneficiaries of Freenome's innovations are healthcare providers and patients seeking early cancer diagnosis and personalized treatment options.

Freenome was discovered on February 3rd 2021 and it currently has a search volume of 8.1K with a growth of +203%.